WU-KONG28 was an open-label, randomized, confirmatory phase 3 study across 16 countries, using blinded independent central ...
With thoracic oncology in the middle of a combinatorial revolution—EGFR-targeted doublets and triplets, a maturing ...
Determining the optimal second-line approach in patients with metastatic clear cell renal cell carcinoma (ccRCC) who have progressed either on 1 or 2 lines of therapy and who had ...
Pooled evidence from 2 randomized trials and 6 observational cohorts suggests posttransplant gilteritinib maintenance may ...
PARADIGM data suggest azacitidine plus venetoclax improves AML event-free survival vs 7+3 with less toxicity; survival looks ...
A patient's chronological age is no longer a barrier to allogeneic stem cell transplant in MDS/MPN, according to David ...
Explore why community and academic oncologists collaborate, share expertise, and deliver faster, more nuanced care for complex patients. The era of the "academic master" is over. Modern oncology ...
Multiple myeloma care shifts to four-drug frontline regimens and MRD testing, boosting deep responses and guiding relapse ...
The 2026 IASLC Targeted Therapies in Lung Cancer meeting brought together leading oncologists, surgeons, and patient ...
Dr. Ajay Nooka, director of the Myeloma program at Winship Cancer Institute of Emory University, simplifies the International ...
In the United States, the vast majority of oncology care is delivered within community-based centers, yet the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results